Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: A randomized controlled trial

BMC Medicine

Volumn 14, Issue 1, 2016, Pages

  Tulloch, Heather E ^a,b   Pipe, Andrew L ^a,b   Els, Charl ^c   Clyde, Matthew J ^a,b   Reid, Robert D ^a,b  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Efficacy; Extended treatment; Intervention; RCT; Smoking cessation

Indexed keywords

CARBON MONOXIDE; NICOTINE GUM; NICOTINE PATCH; VARENICLINE; NICOTINIC AGENT;

ABNORMAL DREAMING; ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COMORBIDITY; CONTINUOUS ABSTINENCE RATE; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; MALE; NAUSEA; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PATIENT COUNSELING; PHYSICAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT DURATION; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIRECTIVE COUNSELING; MIDDLE AGED; PREVENTION AND CONTROL; PROCEDURES; PSYCHOLOGY; SMOKING; TOBACCO USE DISORDER; TREATMENT OUTCOME;

DIRECTIVE COUNSELING; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; TREATMENT OUTCOME; VARENICLINE;

EID: 84974815436     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-016-0626-2     Document Type: Article

References (37)

1. US Department of Health and Human Services. The health consequences of smoking-50 years of progress: A Report of the Surgeon General. Atlanta: USDHHS, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
2. Jha P, Ranson MK, Nguyen SN, Yach D. Estimates of global and regional smoking prevalence in 1995, by age and sex. Am J Public Health. 2002;92:1002-6.
3. Storr CL, Cheng H, Alonso J, et al. Smoking estimates from around the world: Data from the first 17 participating countries in the World Mental Health Survey Consortium. Tob Control. 2010;19:65-74.
4. Borland R, Li L, Driezen P, et al. Cessation assistance reported by smokers in 15 countries participating in the International Tobacco Control (ITC) policy evaluation surveys. Addiction. 2012;107:197-205.
5. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99:29-38.
6. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329.
7. Fiore M, Jaen C, Baker T. Treating tobacco use and dependence: 2008 update: Clinical Practice Guideline. Rockville: US Department of Health and Human Services, Public Health Service; 2008. Report No.: 1437906621.
8. Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: A systematic review and multiple treatment meta-analysis. Ann Med. 2012;44:588-97.
9. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008;63:717-24.
10. Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of five smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009;66:1253.
11. Tsukahara H, Noda K, Saku K. A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study). Circ J. 2010;74:771.
12. Baker T, Piper M, Stein J, Smith S, Bolt D, Fraser D, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: A randomized clinical trial. JAMA. 2016;315(4):371-9.
13. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease a randomized trial. Circulation. 2010;121:221-9.
14. Steinberg MB, Randall J, Greenhaus S, Schmelzer AC, Richardson DL, Carson JL. Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline. Addict Behav. 2011;36:1127-32.
15. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest. 2011;139:591-9.
16. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ. 2012;344:e2856.
17. Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med. 2013;159:390-400.
18. Hong LE, Thaker GK, McMahon RP, et al. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 2011;68:1195-206.
19. McClure JB, Swan GE, Catz SL, et al. Smoking outcome by psychiatric history after behavioral and varenicline treatment. J Subst Abuse Treat. 2010;38:394-402.
20. Weiner E, Buchholz A, Coffay A, et al. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res. 2011;129:94-5.
21. Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73:654-60. doi: 10.4088/JCP.11m07522.
22. Wu BS, Weinberger AH, Mancuso E, et al. A preliminary feasibility study of varenicline for smoking cessation in bipolar disorder. J Dual Diagnosis. 2012;8:131-2.
23. Tulloch H, Pipe A, Els C, et al. Flexible and extended dosing of nicotine replacement therapy or varenicline in comparison to fixed dose nicotine replacement therapy for smoking cessation: Rationale, methods and participant characteristics of the FLEX trial. Contemp Clin Trials. 2014;38:304-13.
24. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43:289.
25. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar G, The M.I.N.I. International Neuropsychiatric Interview (M.I.N.I.). The Development and Validation of a Structured Diagnostic Psychiatric Interview. J Clin Psychiatry. 1998;59(suppl 20):22-33.
26. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K-O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86:1119-27.
27. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 2005;100:299-303.
28. Hedeker D, Mermelstein RJ, Demirtas H. Analysis of binary outcomes with missing data: missing = smoking, last observation carried forward, and a little multiple imputation. Addiction. 2007;102:1564-73.
29. Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry. 2013;170:1460-7.
30. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805.
31. Pasternak B, Svanström H, Hviid A. Use of varenicline versus bupropion and risk of psychiatric adverse events. Addiction. 2013;108:1336-43.
32. Thomas KH, Martin RM, Davies NM, Metcalfe C, Windmeijer F, Gunnell D. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ. 2013;347:f5704.
33. Ebbert JO, Hughes JR, West RJ, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA. 2015;313:687-94.
34. Costa ML, Cohen JE, Chaiton MO, Ip D, McDonald P, Ferrence R. "Hardcore" definitions and their application to a population-based sample of smokers. Nicotine Tob Res. 2010;12:860-4.
35. Warner KE, Burns DM. Hardening and the hard-core smoker: concepts, evidence, and implications. Nic Tob Res. 2003;5:37-48.
36. LeLorier J, Grégoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. NEJM. 1997;337:536-42.
37. Schnoll R, Goelz P, Veluz-Wilkins A, Blazekovic S, Powers L, Leone F, et al. Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Int Med. 2015;175(4):504-11.